Home World News A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across... World News A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 943 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Fear July 26, 2022 Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 Ensuring a Smooth Leadership Transition at NCI April 10, 2019 What to Know About Peer-Reviewed Cancer Information and Its Role in... August 10, 2022 Load more HOT NEWS Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... MGUS to Myeloma: Study Suggests Risk of Progression Can Change FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe... Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas
